Pharmacy Articles

Pharmacy

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Forest Laboratories, Inc. announced positive results from two global multi-center Phase III studies of ceftaroline for the treatment of community-acquired bacterial pneumonia. The top-line data in each of the pivotal trials demonstrate that ceftaroline met the primary objective of non-inferiority and achieved high clinical cure rates compared with ceftriaxone in patients with moderate to severe community-acquired bacterial pneumonia requiring hospitalization.